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Heart failure (HF) is a costly, challenging and highly prevalent medical condition.
Hospitalization for acute decompensation is associated with high morbidity and mortality.
Despite application of evidence-based medical therapies and technologies, HF remains
a formidable challenge for virtually all healthcare systems. Repeat hospitalizations for
acute decompensated HF (ADHF) can have major financial impact on institutions
and resources. Early and accurate identification of impending ADHF is of paramount
importance yet there is limited high quality evidence or infrastructure to guide
management in the outpatient setting. Historically, ADHF was identified by physical exam
findings or invasive hemodynamic monitoring during a hospital admission; however,
advances in medical microelectronics and the advent of device-based diagnostics have
enabled long-term ambulatory monitoring of HF patients in the outpatient setting. These
monitors have evolved from piggybacking on cardiac implantable electrophysiologic
devices to standalone implantable hemodynamic monitors that transduce left atrial or
pulmonary artery pressures as surrogate measures of left ventricular filling pressure.
As technology evolves, devices will likely continue to miniaturize while their capabilities
grow. An important, persistent challenge that remains is developing systems to
translate the large volumes of real-time data, particularly data trends, into actionable
information that leads to appropriate, safe and timely interventions without overwhelming
outpatient cardiology and general medical practices. Future directions for implantable
hemodynamic monitors beyond their utility in heart failure may include management of
other major chronic diseases such as pulmonary hypertension, end stage renal disease
and portal hypertension.
Keywords: heart failure, implantable hemodynamic monitor, thoracic impedance, left atrial pressure monitor,
pulmonary artery pressure monitor, LAPTOP trial, CHAMPION trial
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Introduction
Cardiovascular disease remains the leading cause of death in the
United States and worldwide (Lim et al., 2012; Santulli, 2013).
Heart failure (HF) is a costly, challenging and highly prevalent
medical condition with major public health concerns given the
associated signiﬁcant morbidity and mortality (Ramani et al.,
2010). Hospitalization for acute decompensated heart failure
(ADHF) is a sentinel event that signiﬁes disease progression and
an inability of the heart to maintain adequate hemodynamics
for perfusion and function of vital organs. Nearly half of these
patients are readmitted within 6 months (Jong et al., 2002)
and/or deceased by 1 year (Adams et al., 2005). The lifetime
risk of developing HF for Americans age 40 years or older is
approximately 20% (Yancy et al., 2013) The incidence of new
HF cases exceeds 650,000 annually (Yancy et al., 2013). Over one
million hospitalizations are attributed to HF annually with an
estimated cost of ∼$20 billion for the United States health care
system (Yancy et al., 2013; Sharma et al., 2015).
To contain costs and standardize management of patients
hospitalized for ADHF, the Centers for Medicare and Medicaid
Services have recently introduced regulations to withhold
or reduce payments for unnecessary hospitalizations for HF
(http://CMS.gov)1. Increasingly scrutinized are readmission rates
and other performance metrics (e.g., length of hospital stay,
medical regimen at discharge) that are fuelling eﬀorts to
reduce HF readmissions. Evidence based therapies, including
optimal medical therapy with neurohormonal antagonists and
implantable devices (e.g., cardiac resynchronization therapy,
deﬁbrillators), are well outlined by major cardiovascular and
electrophysiological societies including the American College of
Cardiology, American Heart Association, Heart Failure Society
of America, European Society of Cardiology, European Heart
Rhythm Association, and Heart Rhythm Society (Heart Failure
Society of America et al., 2010; McMurray et al., 2012; Brignole
et al., 2013; Russo et al., 2013; Yancy et al., 2013; Kusumoto et al.,
2014). Despite application of these treatments and technologies,
HF remains a formidable challenge for virtually all healthcare
systems. Moreover, the quality of evidence for care, support and
monitoring systems as well as the infrastructure to support HF
patients, particularly in the outpatient setting, are lacking (Yancy
et al., 2013).
The recent development and clinical trials of implantable
hemodynamic monitoring devices hold promise to reduce HF
hospitalizations, with the potential to improve patient outcomes.
The limited but emerging supportive evidence is encouraging
further eﬀorts to improve the patient experience with this
clinically challenging medical condition. Leading experts in this
ﬁeld have acknowledged the diﬃculty of conducting clinical
trials using cardiac monitoring embedded with therapeutic
management to eﬀect “hard” clinical outcomes and endpoints
(Abraham et al., 2014). They have also underscored the
importance of careful clinical trial design, endpoint selection,
outcome assessment, management of actionable results, and
1CMS.gov. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/Ac
uteInpatientPPS/Readmissions-Reduction-Program.html. Last accessed May 14,
2015.
other ethical issues (Abraham et al., 2014). This review focuses
on implantable hemodynamic monitors that evolved from
electrophysiologic (EP) devices with extended functionality
to dedicated standalone pulmonary artery pressure monitors
(e.g., CardioMEMS™)2 for guiding medical management
of hemodynamic and volume status in outpatients, with
demonstrable eﬀects on reducing hospital readmission.
Historical Background
Early and accurate identiﬁcation of impending and active ADHF
is of paramount importance. Daily weight monitoring is a
low-cost, easily accessible method of monitoring HF patients
both in and out of the hospital. Unfortunately, weight as a
reference value is easily confounded by changes in diet and
muscle mass that are not related to intravascular volume status
or ﬁlling pressures (Wolfel, 2007) and previous studies have
found that the estimated positive predictive value for these
ﬁndings are generally poor (Lewin et al., 2005; Zhang et al., 2009;
Abraham et al., 2011a,b). Furthermore, while telemonitoring and
collaborative multidisciplinary outpatient care teams appear to
be practical eﬀective measures to improve the management of
HF, randomized studies have yet to conﬁrm this (Chaudhry
et al., 2010; Bekelman et al., 2015). The clinical symptoms
of dyspnea, orthopnea, weight gain, and leg edema are often
late indicators of congestion and volume overload that may
already warrant hospitalization. Physical examinationmaneuvers
such as inspection of the jugular venous pressure waveform,
hepatojugular reﬂux and the square wave sign are useful
surrogate measures of cardiac ﬁlling pressures, however, inter-
and intra-observer variability, inconsistent manifestations, and
the need for the patient to present for a physical examination,
limit their applicability to identify early decompensated heart
failure in the outpatient setting (Drazner et al., 1999, 2008).
In addition, the sensitivity and speciﬁcity of these signs
and symptoms vary widely, depending on the clinical study
(Stevenson and Perloﬀ, 1989; McCullough et al., 2002).
A gold standard measure of congestion in HF is not overall
volume status (Verbrugge et al., 2014), but rather the pulmonary
artery occlusion pressure, also known as the pulmonary capillary
wedge pressure (PCWP). The PCWP reﬂects left sided cardiac
ﬁlling pressures and is measured by a pressure transducer on the
end of a pulmonary artery catheter. An inﬂatable balloon on the
distal portion of the catheter allows placement of the catheter
into a sub-selected pulmonary artery (PA) branch. An elevated
PCWP, exceeding 18–22mmHg, indicates pulmonary edema and
congestion. Given the potential dangers of an indwelling PA
catheter for invasive hemodynamic monitoring, the patient is by
convention required to stay in the intensive care unit.
Advancement in medical microelectronics and the advent
of device-based diagnostics have been developed to enable
monitoring of ambulatory HF patients (Table 1). These devices
transmit and report objective, quantitative data via remote
monitoring systems. The premise of monitoring physiologic
2CardioMEMS HF System Post-Approval Study. NCT02279888. https://
clinicaltrials.gov/ct2/show/study/NCT02279888?term=cardiomems&rank=1.
Frontiers in Physiology | www.frontiersin.org 2 October 2015 | Volume 6 | Article 271




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Frontiers in Physiology | www.frontiersin.org 3 October 2015 | Volume 6 | Article 271
Mooney et al. LAP and PAP monitors
parameters is to enable clinicians to use these surrogate
markers to optimize the patients’ medical therapy in the
ambulatory setting, before the onset of acute hemodynamic
decompensation. This concept of remote device monitoring is
also referred to as telemonitoring (Sousa et al., 2014). Several of
the currently available telemonitoring systems measure various
cardiac pressures and tailoring of medical therapy based upon
these pressures is therefore called “pressure guided therapy.”
The basis of pressure guided therapy involves the observation
that most patients with HF require hospitalization because of
excessive ﬂuid accumulation. Accumulation of ﬂuid occurs over
several weeks and eventually reaches a “threshold” that requires
hospitalization (Zile et al., 2008). Knowledge of these pressure
increases can thus allow adjustment of medications to avoid
reaching this “threshold” (Figure 1).
Early investigational, implantable heart function monitoring
devices piggybacked on the existing implantable cardioverter
deﬁbrillator (ICD) technology which had already established the
safety of right ventricular pacing leads and was being used in
the target population. Early devices used innovative transvenous
lead technology to provide mixed venous oxygen saturation and
pressures in the right ventricle (RV) (Ohlsson et al., 1996, 1998).
The correlation between RV end diastolic pressure and PA end
diastolic pressure was demonstrated. In addition, these devices
also could measure additional physiologic parameters such as
heart rate variability, body temperature, and other surrogates
of patient activity levels (Raina et al., 2015). Information
management varied and early models initially only provided real-
time data during interrogations in the oﬃce. Later designs gained
the capacity to store data and to transfer it securely and remotely.
These devices culminated in the development of the Chronicle R©
IHM (IHM-2; Model 9520) (Figure 2A). The IHM-1 and IHM-2
devices have demonstrated signiﬁcant changes in RV pressures
associated with changes in diuretic therapy (Braunschweig et al.,
2002), β-adrenergic receptor blockers (Ishikawa et al., 2009),
biventricular pacing (Bruns et al., 2005), and inhaled therapies
for pulmonary hypertension patients (Fruhwald et al., 2003;
Karamanoglu et al., 2007).
Intrathoracic impedance monitoring was also evaluated as an
adjunct to monitoring heart failure patients with an indication
for an ICD or cardiac resynchronization therapy deﬁbrillator
(CRT-D) (Braunschweig et al., 2004; Yu et al., 2005). The
OptiVol R© function, an exclusive technology of Medtronic
(Minneapolis, MN, USA) received the United States Food and
Drug Administration (FDA) approval in 20043. ICD devices
with OptiVol can longitudinally monitor the conductance of
a microelectrical current between the RV deﬁbrillating coil
and device case. When the ﬂuid index sharply rises above the
baseline in conjunction with a decrease in thoracic impedance,
intrathoracic ﬂuid accumulation such as pulmonary congestion
is suggested. Elevated left ventricular (LV) ﬁlling pressure is
associated with increased intrathoracic ﬂuid (i.e., lung water),
which in turn is associated with increased conductance and




FIGURE 1 | (A) Pulmonary artery (PA) pressures rise over time and cross a
“threshold”; this results in decompensated heart failure and hospitalization. (B)
When the rise in PA pressure is identified and additional diuretic therapy is
given, the threshold is not crossed and hospitalization is avoided.
decreased impedance as this current travels across lung tissue.
Other concomitant device data including heart rate variability,
resting night heart rate, patient activity level, and the burden of
atrial tachycardia or ﬁbrillation noted around the time of changes
in Optivol ﬂuid index and thoracic impedance trends may help
to improve conﬁdence in interpretation of potentially actionable
data. Initial trials demonstrated increased sensitivity for early
detection of HF exacerbations with decreased unexplained
alarms in comparison to the traditional weight based monitoring
protocol (Abraham et al., 2011b).
Ambulatory monitoring of intrathoracic impedance has
not had the clinical impact that was initially anticipated, with
statistically non-signiﬁcant results from several contemporary
trials (Conraads et al., 2011; Yang et al., 2013) Contributing
factors likely include the diﬃculty determining the diﬀerence
between appropriate detection of pre-clinical events and false
alarms, as well as the need for third party involvements to
monitor trends and eﬀect appropriate therapeutic changes.
Threshold changes in impedance can also occur from non-
cardiac etiologies (e.g., pneumonia, pneumothorax, positive
pressure ventilation), pointing to the importance of interpreting
those data in association with other concomitant device data,
as well as clinical data from a (phone) discussion with the
patient. Furthermore, monitoring of electrophysiology (EP)
devices is traditionally far removed from those empowered to
make changes in a patient’s HF medications and arrange for
appropriate follow up. A recent retrospective review of the
data from the Fluid Accumulation Status Trial (FAST) and
Program to Access and Review Trending Information and
Evaluate Correlation to Symptoms in Patients With Heart
Failure (PARTNERS-HF) trials by Abraham and colleagues
suggested a novel scheme to stratify patients at risk for a HF
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FIGURE 2 | Implantable ambulatory heart failure hemodynamic monitors. (A) Chronicle®: (top left to bottom right) Implantable RV lead and ICD; lateral and
posterior-anterior chest radiographs after device placement. (B) HeartPOD®. Implantable left atrial device and distal anchor. (C) CardioMEMSTM HF System:
(i) pulmonary artery (PA) sensor; (ii) delivery catheter with preloaded PA sensor; (iii) pulmonary arteriograms showing a radiopaque PA sensor in a segmental branch of
the left pulmonary artery (PA) before (left) and after (right) contrast dye injection; (iv) patient electronics system for transmission of data. All images were adapted with
permission from Medtronic, Inc., St. Jude Medical, Inc., and Elsevier Inc.
related hospitalization using diagnostic physiologic monitoring
parameters germane to most modern ICD devices (Sharma et al.,
2015). Increasing numbers of device observations correlated
with an increased risk of a HF hospitalization. However, as
demonstrated in prior studies, rates of HF hospitalizations
associated with alerts were low, around 14% for ≤3
observations.
In contrast to prior eﬀorts that combined HF monitoring
therapies with therapeutic EP devices, the left atrial pressure
(LAP), and pulmonary artery pressure (PAP) ambulatory heart
failure monitoring implantable devices were developed as purely
diagnostic devices (Figures 2B,C). LAP monitoring was being
explored around the same time that intrathoracic impedance
was in the early post-marketing surveillance period (Ritzema
et al., 2007). The LAP monitoring device incorporates direct
left atrial pressure monitoring via a pressure transducer secured
to the interatrial septum. Transvenous access and a transseptal
puncture are required for implantation (see Table 2). Similar to
early EP devices, LAP monitors (HeartPOD R©, St. Jude Medical
Inc, Sylmar, CA, USA) can transfer data through radiofrequency
wireless transmissions done by direct interrogation of the coil
antenna using the handheld patient advisory module (PAM R©)
(Figure 1B). The Hemodynamically Guided Home Self-Therapy
in Severe Heart Failure Patients (HOMEOSTASIS) trial was
published in 2011 and reported the safety, feasibility, accuracy,
and reliability of LAP monitoring (Troughton et al., 2011).
The Left Atrial Pressure Monitoring to Optimize Heart Failure
Therapy Study (LAPTOP-HF) trial was designed to determine
the safety and clinical eﬀectiveness of a physician-directed,
patient self-management therapeutic strategy, and has recently
been completed; results are eagerly awaited (Maurer et al., 2015).
Monitoring of PAP has been used for decades by cardiologists
to detect early signs of HF in the intensive care setting
(Rutherford et al., 1971). For ambulatory PAP monitoring,
CardioMEMS (St. Jude Medical Inc, Sylmar, CA) was developed
to directly measure systolic, diastolic and mean PAPs using
a miniaturized wireless electromechanical sensor implanted in
conjunction with a right heart catheterization procedure via
transvenous access (Figure 1C). As the sole FDA-approved
standalone device for outpatient HF monitoring, CardioMEMS
was tested and proven to signiﬁcantly reduce admissions for
patients with New York Heart Association functional class III HF,
regardless of left ventricular ejection fraction (LVEF) (Abraham
et al., 2011a; Adamson et al., 2014), even in those with HF with
preserved LVEF as opposed to those with reduced LVEF. A large
post-approval trial is already recruiting (goal N = 1200) to
verify the robustness, safety and usefulness of CardioMEMS in
the complex real-world setting, particularly in reducing the rate
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TABLE 2 | Procedural characteristics.
LAP monitor PAP monitor
Device HeartPOD® CardioMEMS™
Access Venous (femoral and subclavian vein) Venous (usually femoral)
Approach Transseptal puncture Via PA
Accessories Brockenbrough needle through 8 Fr sheath, 11 Fr delivery
sheath in LA
12 Fr introducer sheath, dilators with access guidewire,
110-cm PA catheter, 0.018′′ x 260–300 cm fixed core
guidewire with straight or angled tip
Intraprocedural anticoagulation Heparin 5000 IU, intravenous None
Imaging Fluoroscopy, echocardiography (including TEE, TTE, ICE) Fluoroscopy, pulmonary arteriography
Method and location of sensor deployment Cinching and fixation of device anchors to inter-atrial
septum
Release of preloaded sensor from over-the-wire delivery
catheter
Associated implantable components Coil antenna and lead None
Duration of procedure >1 h 20min
Device interrogation Transcutaneous detection of implanted sensor
lead-antenna coil signal using handheld patient advisory
module (PAM)
Transcutaneous detection of sensor-released energy in
response to radiofrequency pulse from patient
electronics unit
Post-procedural antithrombotics Aspirin and warfarin for 30 days, then aspirin indefinitely Aspirin and P2Y12 inhibitor (clopidogrel) for 1 month,
then aspirin indefinitely; warfarin may substitute for
aspirin after the first month if chronic anticoagulation
therapy is required
Duration of implantation Lifelong Lifelong
Fr, French gauge; IU, international units; LA, left atrium; PA, pulmonary artery; ICE, intracardiac echocardiography; TEE, transesophageal echocardiography; TTE, transthoracic
echocardiography.
of HF hospital readmissions and in improving patients’ quality of
life (clinicaltrials.gov).
Deployment and Monitoring
The Chronicle features a programmable device that bears
resemblance to a pacemaker pulse generator, which is implanted
to process and store information from the pressure sensor near
the tip of the transvenous lead (Bourge et al., 2008). The device
continuously records data such as heart rate, body temperature,
estimated patient activity level, RV systolic and diastolic pressure,
RV pressure changes, and estimated PA diastolic pressure.
It is only programmed to store a smaller dataset based on
programmed intervals, recording the median 6th and 94th
percentile levels over that period. In the COMPASS-HF trial,
patients were asked to use a handheld radio frequency device
to transmit readings at least once weekly using a telephone line.
Information was stored on a secure server that clinicians could
access through a secure web site.
The device characteristics and key aspects of deployment
of the HeartPOD and CardioMEMS are summarized in
Table 2. The HeartPOD system consists of a microelectronic
sensor and diaphragm housed in a cylindrical titanium casing
(approximately 3mm × 7mm) equipped with deployment
anchors, and linked with an implantable sensor lead and a coil
antenna within a can that resembles a pacemaker (Figure 1B).
After gaining femoral venous access, a Brockenbrough needle
and transseptal sheath are advanced, and puncture of the
interatrial septum is performed. Thereafter, a guidewire is
introduced via a subclavian vein to secure the transseptal location
and a delivery sheath is placed to allow for placement of the
sensor lead and LA sensor. Once the correct position is conﬁrmed
with intracardiac or transesophageal echocardiography, the LA
sensor with the implantable sensor lead is deployed. The sensor
is oriented to the LA and is buttressed and immobilized
permanently with proximal and distal nitinol anchors on the
respective right and left atrial sides of the interatrial septum upon
deployment. The electrode is then transferred from the femoral
location to the infraclavicular position via an exchange catheter
and attached to communication module. The metal alloy can,
referred to as the implantable communications module or ICM,
containing the coil antenna and microelectronics is implanted
in the same manner as for a pacemaker. A prospective open-
label observational study of 84 patients found that freedom from
device failure was 95% at 2 years and 88% at 4 years (Troughton
et al., 2011).
CardioMEMS is a battery-free, leadless sensor (15mm ×
3mm) consisting of a coil and capacitor encased in silicone, with
a nitinol wire loop at each end of the sensor (Figure 2Ci). The
CardioMEMS device is preloaded on a delivery catheter with
a tether release system (Figure 2Cii). The design of the system
is based on microelectromechanical principles of resonance
whereby an external antenna wand emitting radiofrequency
energy can cause varying degrees of oscillations in the sensor
depending on the ambient pressure. The implanting procedure
requires a transfemoral venous approach for accommodation
of a 12-French introducer sheath for the CardioMEMS delivery
catheter (Table 2). PA catheterization is performed to document
right sided pressures before and after device implantation. After
identifying a posterior segmental branch of the left PA by
selective pulmonary arteriography (Figure 2Ciii), the sensor is
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liberated as the tether release wire is pulled and withdrawn
while the nitinol loops uncoil from the delivery catheter to
maintain device position in the PA branch. Interrogation of PAP
requires the patient to be in a supine position with the supplied
pillow-like wand placed underneath the patient (Figure 2Civ).
After approximately 20 s, systolic, diastolic and mean PAPs are
measured and transmitted via wireless cellular network to the
CardioMEMS data center. In the landmark CardioMEMS Heart
Sensor Allows Monitoring of Pressure to Improve Outcomes in
NYHA Class III Heart Failure Patients (CHAMPION) trial, the
device- or system-related complication rate was only 1.4%, with
an overall pressure-sensor failure rate of 0% (Abraham et al.,
2011a).
Patients enrolled in the CHAMPION trial were asked to
make daily measurements of their PAPs using their portable
electronic unit and a special pillow containing an antenna to
take daily sensor readings which are transmitted through a
modem or cellphone to a secure patient database (Adamson
et al., 2011). By requesting patients to lay on the special pillow,
measurements should be more consistent reproducible and
ideally leveled. In the LAPTOP-HF trial, LAP, body temperature,
and intracardiac electrogram were measured. Subjects were able
to power and interrogate their devices with radiofrequency
wireless transmissions from their patient activator module or
PAM (Ritzema et al., 2007), with capacity to store up to 3 months’
data if 6 waveforms are acquired daily.
Both the HeartPOD and CardioMEMS systems use a
physician-guided self-management model that is intuitive
and conceptually sound. However, experts in the ﬁeld have
universally acknowledged the challenges in conducting
implantable monitoring trials to demonstrate impacts on clinical
outcomes, particularly with how the interrogated physiologic
data are handled (Abraham et al., 2014). Monitoring of device
data requires patient compliance, “physician compliance” and
a structured action plan or algorithm in order to execute a
successful program. Achieving the goal of reducing patient
hospitalization and readmission for HF requires a team eﬀort
involving the patient, caretaker, primary care physician,
cardiologist, nurse and/or support staﬀ. As a team, they
will need suﬃcient resources and training to appropriately
interpret data trends. Standard easy to use protocols would
lead to more uniform management and optimize the ability
to study IHMs. These protocols will need to have some
ﬂexibility so health care providers can customize treatment
plans to each individual as necessary. In monitoring data,
it has been emphasized that data trends are more crucial to
successful management than acting on individual abnormal
data points. Potential harm could also be introduced with
injudicious remote monitoring when treatments such as diuretic
therapy and vasodilators are administered without careful
consideration, understanding and interpretation of abnormal
data. Establishing a good line of communication with the
patient, and exercising clinical judgment (e.g., focused history
taking to gather clinical cues, scheduling an outpatient visit
when required, and assessing renal function and/or electrolytes
after adjustment of medical therapy such as diuretics), may
help to clarify abnormal and outlying data trends. An online
secure website (https://cardiomemshf.com/user/sign_in) is
accessible to healthcare professionals to view the interrogated
data. The HeartPOD, CardioMEMS and other non-
EP (i.e., without pacemaking or deﬁbrillator functions)
implantable monitoring systems have built-in, untapped
features including cardiac output, heart rate variability, and
electrocardiographic monitoring. If oﬃcially approved by
the FDA, these additional monitoring parameters will likely
improve characterization of hemodynamic derangements, and
potentially reduce false-positive results, and associated resource
utilization.
When using surrogate measures to direct therapy, it is crucial
to understand exactly what is being measured. While mean PAP
and LAP are both considered adequate surrogates for ﬁlling
pressures, they are two diﬀerent measurements and neither is
the gold standard measurement (LVEDP). The PCWP is often
considered to reﬂect left ventricular preload and pulmonary
capillary hydrostatic pressure, however, there is ongoing debate
about the validity of this assumption in the setting of various
conditions including chronic pulmonary disease, mechanical
ventilation and pulmonary venous scarring. In principal, the LAP
would be a more accurate measurement as it is physically and
physiologically closer to the gold standard, LVEDP, however it is
more invasive to measure. A brief literature review did not reveal
any studies comparing the three measurements simultaneously,
however there are a few studies comparing LAP and PCWP. In
1962, the PAP, PCWP, and LAP measurements of 11 patients
with either clinically normal hearts or suspected mitral valve
disease were studied with right heart catheterization in a control
state, during a norepinephrine infusion, and during positive and
negative intraalveolar pressures (Luchsinger et al., 1962). This
study demonstrated a strong linear relationship (r = 0.95)
between PCWP and LAP in all settings with the PCWP being
consistently 35% higher than the LAP. A more contemporary
study of lightly sedated dogs reported that the mean PCWP
accurately reﬂected LAP (Chaliki et al., 2002). In this study,
mean PCWP again was highly correlated with LAP (r = 0.99;
slope = 0.99; intercept = −0.46mmHg). However, a study of 43
dogs and 30 patients in severe hemorrhagic, traumatic or septic
shock noted that a dangerous rise in PAP was not reﬂected by
PCWP or even central venous pressure (Hardaway, 1982). This
discrepancy was attributed to suspected partial obstruction of the
pulmonary microcirculation due to disseminated intravascular
coagulation in the pulmonary venules. Central venous pressure
should only rise due to high pulmonary pressures if there is RV
failure.
With IHM, it is not only the sites fromwhich data are collected
but the manner in which they are recorded, stored and reported.
In the HOMEOSTASIS trial, subjects were requested to make
two LAP measurements a day with additional measurements
during symptoms (Troughton et al., 2011). In the CHAMPION
trial, continuous PAP measurements are recorded (Abraham
et al., 2011a). Clearly, there are tradeoﬀs between the challenge
of requiring patients in the real world to make multiple daily
recordings using a separate handheld device and voluminous
amounts of data that require no input from patients to
collect.
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Clinical Evidence for Ambulatory
Monitoring Implantable Cardiovascular
Devices
As already seen with implantable cardiovascular devices, there is
a wealth of data that can be harnessed throughminimally invasive
means and transmitted to a secure data repository via remote
wireless technology. Newer implantable cardiac monitoring
devices for HF oﬀer the ability to provide individualized data
trends and ideally predict clinical events before they occur.
However, isolated device alerts need to be used in conjunction
with other clinical data to avoid overutilization of health care
resources and increased hospitalizations. Successful translation
of remote device based monitoring into successful clinical
management of these patients will require simple prospectively
validated algorithms that indicate how to use raw data from
individual devices to make timely and appropriate changes in
clinical management without overburdening staﬀ. At this time,
despite a wealth of smaller studies evaluating these devices
(Table 3), larger clinical radnomized trials are still necessary
to demonstrate that implantable device based hemodynamic
sensors beneﬁcially impact morbidity and mortality in HF
patients.
Future of Ambulatory Heart Failure
Implantable Cardiovascular Monitoring
Devices
Future directions for remote implantable PAP and LAP devices
are broad. In cardiac patients, one can easily imagine the role for
these devices in better understanding exercise physiology. They
could also aid in clarifying the hemodynamics in particularly
challenging outpatients such as those with diﬃcult to assess
pulmonary pressures by echocardiography (e.g., rheumaticmitral
valve disease, severe pulmonary hypertension, morbidly obese
patients.) Furthermore, in advanced HF patients with known
arrhythmias, there can be a role to assess the clinical impact
of supraventricular arrhythmias such as atrial ﬁbrillation and
ventricular arrhythmias, as well as addressing the question of
whether these rhythm disturbances are causal or secondary to
ADHF. Additionally, with the pressure to avoid indwelling lines,
invasive procedures and overburdening intensive care units, pre-
existing internal devices that monitor ﬁlling pressures could
facilitate the management of these particularly high risk patients
when admitted for both cardiac and non-cardiac issues, including
perioperative hemodynamic and ﬂuid management.
In advanced HF patients with left ventricular assist devices
(LVAD) who are recurrently admitted with symptoms of
congestion and ﬂuid overload, LAP and PAP monitors may
potentially help to discern elevated left sided ﬁlling pressures
from other causes of dyspnea, and volume overload (e.g., chronic
kidney disease progression, hypoalbuminemia, protein-losing
enteropathy). However, further clinical review and evaluation
still may be necessary to exclude a failing right ventricle in
response to LVAD placement and manage other non-cardiac
etiologies for recurrent hospitalizations. These devices may also
be able to detect low ﬁlling pressures in patients with LVADs
who urgently need increased intravascular volume in order
for optimal device function and cardiac output. It remains
to be seen whether regulatory agencies and transplantation
societies will endorse the use of implantable LAP or PAP
monitors as an alternative to indwelling PA catheters in
the pre-heart transplant setting, with the intent to obviate
the need for hospitalization in the intensive care unit and
periodic replacement of PA catheters that are associated with
procedural and other risks including line infection, sepsis, and
thromboembolism.
There are also innumerable non-cardiac scenarios in which
continuous assessment of cardiac hemodynamics and ﬁlling
pressures would be invaluable. A recently published substudy
of the CHAMPION trial found that of the 217 patients who
did not meet criteria for pulmonary hypertension during the
implantation right heart catheterization, 48.8% (N = 16)
met criteria based on continuously observed PAP over the
ﬁrst week post-implantation. This implies that an implantable
heart monitor may assist with improved diagnosis of pulmonary
hypertension and perhaps better guide future trials targeting
pulmonary hypertension (Frantz et al., 2008). It is foreseeable
that future clinical investigations using these hemodynamic
monitors may extend to non-HF patients, especially in eﬀorts
to improve management of volume status in the outpatient
setting, improve patients’ quality of life, and reduce rates of
hospital readmission for hypo- or hypervolemia. Patients with
end stage renal disease, primary pulmonary hypertension or
portal hypertension are patient populations with similar high
healthcare utilization. Renal replacement and diuretic therapies
usually target a patient’s known “dry weight,” which, as discussed
above, is often not an accurate or reliable measure of true volume
status. Furthermore, implantable hemodynamic monitors can
detect other clinically signiﬁcant events, such as poorly tolerated
arrhythmias or hemodynamic shifts, that may be aﬀecting
patients and were previously unappreciated (Braunschweig et al.,
2006).
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